ArticleBlood and lymphatic cancer : targets and therapy2025
Clinical Characteristics, Prognostic Risk Factors, and Primary Treatment for Elderly Patients with Primary Central Nervous System Lymphoma: A Seer Database-Based Research.
Article in Blood and lymphatic cancer : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.International journal of cancer · 2026Article
- The Changing Face of HIV-Associated Malignancies: Is this the Same in Turkey As Well?Current HIV research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary central nervous system lymphoma (PCNSL) is a highly aggressive extranodal non-Hodgkin's lymphoma. Moreover, there is currently no specific prognostic model for elderly PCNSL patients. Methods: This study retrospectively selected patients diagnosed with PCNSL between 1975 and 2016 from the National Cancer Institute Surveillance, Epidemiology, and End Results Database (SEER NCI). The COX model was used to determine the risk factors for overall survival (OS) and disease-specific survival (DSS). The prognostic prediction models for DSS and OS were developed by integrating significant covariates identified through multivariate analysis. Results: A total of 3,554 patients with PCNSL were included in this retrospective study based on inclusion and exclusion criteria. Significant differences exist in clinical profiles between elderly (≥60 years) and younger (<60 years) patients with PCNSL. The results showed that the age at diagnosis, pathological subtype, whether or not they have undergone surgical treatment, and whether or not they have received chemotherapy are independent risk factors for DSS, among elderly PCNSL patients. In addition to the risk factors, etc for DSS, human immunodeficiency virus (HIV) infection was also an independent risk factor for OS. Based on this, we developed nomograms to estimate OS and DSS for 1, 2, and 3 years. Conclusion: This study found differences in baseline data between elderly PCNSL patients and younger PCNSL patients. Surgery and chemotherapy are associated with better OS and DSS. However, in the long run, radiotherapy is not beneficial to OS and DSS of elderly PCNSL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.